drugset
drugset / Trial / NCT05660993

Multicenter Study of Safety and Efficacy of PET-adapted Treatment With Nivolumab, Bendamustine, Gemcitabine, Vinorelbine (Nivo-BeGEV) in Patients With Relapsed/Refractory Hodgkin Lymphoma

NCT05660993 ↗

Phase 2 Unknown 50 enrolled National Research Center for Hematology, Russia
NaSingle-groupOpen-labelTreatment

Summary

Nivolumab is an anti-PD-1 antibody highly effective in patients with relapsed/refractory classical Hodgkin lymphoma. A PET-adapted regimen of nivolumab combined with salvage therapy was shown to induce high response rates and favorable progression-free survival as a bridge to autologous stem cell transplantation, allowing to omit salvage chemotherapy in a substantial proportion of r\\r cHL patients. This study evaluates the safety and efficacy of PET-adapted treatment of nivolumab at the 3 mg/kg in combination with Bendamustine, Gemcitabine, Vinorelbine (Nivo-BeGEV) in patients with relapsed/refractory Hodgkin Lymphoma.

Timeline

Start
2019-08-19
Primary completion
2025-03-01
Completion
2025-03-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Bendamustine Small molecule 90 mg/m2 —
Subject Gemcitabine Small molecule 800 mg/m2 —
Subject Nivolumab Monoclonal antibody 3 mg/kg —
Subject Vinorelbine Small molecule 20 mg/m2 —

Indications

Hodgkins lymphoma